Primary Immunodeficiency Diseases (PIDs) are rare diseases which can be
studied most effectively using transnational co-operation, which would enable
the maximum number of cases to be examined. Although rare, they affect around 60 000
patients across Europe. Within that total, there are more than 100 different forms of PIDs,
with a further 100 expected to be identified over the next ten years. This diversity
poses a considerable challenge to researchers and clinicians. In addition,
the diseases are difficult to diagnose, frequently require complex treatment
regimens, and the genetic basis of many of them is not known.
EURO-POLICY-PID will promote the international collaboration needed to sustain and develop Europe’s
world-leading position in research on primary immunodeficiency diseases.